GBT Announces Participation at the Cantor Global Healthcare Conference
September 20, 2021 08:00 ET
|
Global Blood Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Sept. 20, 2021 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that it will participate in a virtual fireside chat at the Cantor...
GBT ruft Stiftung ins Leben mit dem Ziel, benachteiligten Patientengruppen weltweit eine bessere Versorgung und Unterstützung zu ermöglichen
September 14, 2021 11:00 ET
|
Global Blood Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Sept. 14, 2021 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) hat die Gründung der GBT Foundation bekannt gegeben. Die Stiftung agiert als...
GBT inaugure sa Fondation, pour améliorer la santé et le bien-être de communautés de patients défavorisés le monde
September 14, 2021 11:00 ET
|
Global Blood Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., 14 sept. 2021 (GLOBE NEWSWIRE) -- Global Blood Therapeutics Inc. (GBT) (NASDAQ: GBT) a annoncé le lancement de sa Fondation, une organisation dédiée à améliorer la santé...
GBT Establishes The GBT Foundation to Improve the Health and Well-being of Underserved Patient Communities Around the World
September 14, 2021 11:00 ET
|
Global Blood Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Sept. 14, 2021 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) announced the launch of The GBT Foundation, a 501(c)(3) organization and source of...
GBT Announces New Employment Inducement Grants
September 09, 2021 08:00 ET
|
Global Blood Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Sept. 09, 2021 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that on September 1, 2021, the compensation committee of GBT’s...
GBT and Sickle Cell Disease Association of America to Host 10th Annual Sickle Cell Disease (SCD) Therapeutics Conference
September 08, 2021 17:05 ET
|
Global Blood Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif. and BALTIMORE, Sept. 08, 2021 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) and the Sickle Cell Disease Association of America, Inc. (SCDAA)...
U.S. FDA Accepts for Priority Review Supplemental New Drug Application for Oxbryta® (voxelotor) for the Treatment of Sickle Cell Disease in Children Ages 4 to 11
September 07, 2021 08:00 ET
|
Global Blood Therapeutics, Inc.
New Drug Application for Oxbryta dispersible tablets also accepted for priority review Approximately 17,000 children ages 4 to 11 years have sickle cell disease in the United States SOUTH SAN...
GBT Announces Participation in Upcoming Investor Conferences
September 02, 2021 08:00 ET
|
Global Blood Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Sept. 02, 2021 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that it will participate in virtual fireside chats at the...
GBT Announces New Employment Inducement Grants
August 12, 2021 08:00 ET
|
Global Blood Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Aug. 12, 2021 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that on August 1, 2021, the compensation committee of GBT’s board...
GBT Announces Participation at the Wedbush PacGrow Healthcare Conference
August 04, 2021 08:00 ET
|
Global Blood Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Aug. 04, 2021 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that it will participate in a virtual fireside chat at the Wedbush...